1992
DOI: 10.3349/ymj.1992.33.2.137
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: We have studied the patterns of P-glycoprotein expression before and after 3 cycles of induction chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) using immunohistochemically stained paraffin-embedded specimen of 28 patients with locally advanced breast cancer. The frequency of P-glycoprotein expression in untreated breast cancer turned out to be very low: only one out of 28 untreated, biopsy specimen at the time of diagnosis was positive. The frequency of P-glycoprotein expression was markedly in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
24
1

Year Published

1996
1996
2018
2018

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(30 citation statements)
references
References 0 publications
5
24
1
Order By: Relevance
“…The only common characteristics shared by these substrates are that most of these compounds are hydrophobic, positively charged or neutral compounds with a planar structure (Gottesman and Pastan, 1993;Kusuhara et al, 1998); however, negatively charged compounds, such as methotrexate and phenytoin, have also been reported as P-glycoprotein substrates Norris et al, 1996;Potschka and Loscher, 2001). P-glycoprotein is frequently detected in various resistant human tumors and often predicts poor prognosis (Chan et al, 1991;Dalton, 1994;Gregorcyk et al, 1996;Koh et al, 1992;List, 1996;Marie et al, 1991;Nooter and Sonneveld, 1994;van der Zee et al, 1995;Zochbauer et al, 1994). Thus, Pglycoprotein is believed to be one of the major mechanisms for MDR and represents a pharmacological target for reversing MDR.…”
Section: Flavonoid-p-glycoprotein (Abcb1) Interactionsmentioning
confidence: 93%
“…The only common characteristics shared by these substrates are that most of these compounds are hydrophobic, positively charged or neutral compounds with a planar structure (Gottesman and Pastan, 1993;Kusuhara et al, 1998); however, negatively charged compounds, such as methotrexate and phenytoin, have also been reported as P-glycoprotein substrates Norris et al, 1996;Potschka and Loscher, 2001). P-glycoprotein is frequently detected in various resistant human tumors and often predicts poor prognosis (Chan et al, 1991;Dalton, 1994;Gregorcyk et al, 1996;Koh et al, 1992;List, 1996;Marie et al, 1991;Nooter and Sonneveld, 1994;van der Zee et al, 1995;Zochbauer et al, 1994). Thus, Pglycoprotein is believed to be one of the major mechanisms for MDR and represents a pharmacological target for reversing MDR.…”
Section: Flavonoid-p-glycoprotein (Abcb1) Interactionsmentioning
confidence: 93%
“…MDR1/P-glycoprotein is the best characterized factor of the efflux system mediating therapy resistance [5,6]. A number of clinical investigations [7][8][9][10][11][12][13][14][15][16][17][18] have suggested that intrinsic or acquired overexpression of MDR1/P-glycoprotein resulted in a poor clinical outcome of chemotherapy ( Table 1). In this review, the current state of knowledge of MDR1/P-glycoprotein and the modulation of MDR by targeting MDR1/P-glycoprotein is summarized based on the latest report along with future perspectives for the reversal of MDR1/P-glycoprotein-mediated MDR.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to cancer cells, P-glycoprotein is expressed in epithelial cells of normal tissues involved in drug disposition including the liver, intestine, and kidney while providing a barrier to sites such as the brain and testes (Marzolini et al, 2004). P-Glycoprotein expression has been noted to be highly variable in primary breast tumors (detection ranging from 9 to 50% of tumors examined) and is significantly increased after treatment with chemotherapeutic agents; however, its significance to chemotherapy clinical response remains controversial (Koh et al, 1992;Tsukamoto et al, 1997;Rudas et al, 2003;Larkin et al, 2004;Atalay et al, 2006). Several reports determined that P-glycoprotein expression appears to be higher in more aggressive, locally advanced or metastatic tumors and is associated with a shorter overall survival for tamoxifen-treated patients, suggesting its use as a putative prognostic factor (Schneider et al, 1994;Linn et al, 1995;Tsukamoto et al, 1997).…”
Section: Introductionmentioning
confidence: 99%